NEW YORK (GenomeWeb News) - Mayo Clinic will provide genetic tests and other services using Luminex’s xMAP technology and will work with Luminex to develop testing for the blood disorder thalassemia under a new licensing and development collaboration, the company said today.
The program includes collaboration and licensing provisions for inherited thalassemia and allows for the development of additional tests as well, Luminex said.
With xMAP, Mayo Clinic will add to its thalassemia services a molecular diagnostic test using multiplex ligation-dependent probe amplification and bead-based liquid microarray technology.
Thalassemia, which is also called Mediterranean anemia, is a blood disorder caused by genetic defects that result in reduced blood cells. Around two million people in the US carry the genetic trait for the disease, the company said.
Financial terms of the agreement were not released.